Cargando…

18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting

Recent improvements in alveolar echinococcosis (AE) therapy can provide long-term disease control, and even allow structured treatment interruption in selected cases. Imaging has a pivotal role in monitoring disease activity, with 18-fluoro-deoxyglucose positron emission and computed tomography (18F...

Descripción completa

Detalles Bibliográficos
Autores principales: Eberhardt, Nina, Peters, Lynn, Kapp-Schwoerer, Silke, Beer, Meinrad, Beer, Ambros J., Grüner, Beate, Thaiss, Wolfgang M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951377/
https://www.ncbi.nlm.nih.gov/pubmed/35335672
http://dx.doi.org/10.3390/pathogens11030348
_version_ 1784675371121115136
author Eberhardt, Nina
Peters, Lynn
Kapp-Schwoerer, Silke
Beer, Meinrad
Beer, Ambros J.
Grüner, Beate
Thaiss, Wolfgang M.
author_facet Eberhardt, Nina
Peters, Lynn
Kapp-Schwoerer, Silke
Beer, Meinrad
Beer, Ambros J.
Grüner, Beate
Thaiss, Wolfgang M.
author_sort Eberhardt, Nina
collection PubMed
description Recent improvements in alveolar echinococcosis (AE) therapy can provide long-term disease control, and even allow structured treatment interruption in selected cases. Imaging has a pivotal role in monitoring disease activity, with 18-fluoro-deoxyglucose positron emission and computed tomography (18F-FDG-PET/CT) in particular having proven beneficial for assessing disease activity. Repetitive regular examinations to monitor therapy response, however, can lead to substantial radiation burden. Therefore, by combining metabolic information and excellent tissue contrast in magnetic resonance imaging (MRI), PET/MR appears ideally suited for this task. Here, we retrospectively analyzed 51 AE patients that underwent 18F-FDG-PET/MR. Patients had a ‘confirmed/probable’ diagnosis in 22/29 cases according to the WHO classification. FDG uptake, diffusion restriction, and MRI morphology were evaluated. We found significant differences in FDG uptake between responders to benzimidazole therapy and progressive manifestations (SUVavg 2.7 ± 1.3 vs. 5.4 ± 2.2, p < 0.001) as well as between Kodama Types 1 and 3 (F = 9.9, p < 0.003). No significant differences were detected for ADC values or MRI morphology concerning response and no correlations were present between FDG uptake and ADC values. The mean radiation dose was 5.9–6.5 mSv. We conclude that the combination of metabolic information and MRI morphology at a low radiation dose proposes PET/MR as a suitable imaging modality for AE assessment. Longitudinal studies are needed to define the role of this imaging modality.
format Online
Article
Text
id pubmed-8951377
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89513772022-03-26 18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting Eberhardt, Nina Peters, Lynn Kapp-Schwoerer, Silke Beer, Meinrad Beer, Ambros J. Grüner, Beate Thaiss, Wolfgang M. Pathogens Article Recent improvements in alveolar echinococcosis (AE) therapy can provide long-term disease control, and even allow structured treatment interruption in selected cases. Imaging has a pivotal role in monitoring disease activity, with 18-fluoro-deoxyglucose positron emission and computed tomography (18F-FDG-PET/CT) in particular having proven beneficial for assessing disease activity. Repetitive regular examinations to monitor therapy response, however, can lead to substantial radiation burden. Therefore, by combining metabolic information and excellent tissue contrast in magnetic resonance imaging (MRI), PET/MR appears ideally suited for this task. Here, we retrospectively analyzed 51 AE patients that underwent 18F-FDG-PET/MR. Patients had a ‘confirmed/probable’ diagnosis in 22/29 cases according to the WHO classification. FDG uptake, diffusion restriction, and MRI morphology were evaluated. We found significant differences in FDG uptake between responders to benzimidazole therapy and progressive manifestations (SUVavg 2.7 ± 1.3 vs. 5.4 ± 2.2, p < 0.001) as well as between Kodama Types 1 and 3 (F = 9.9, p < 0.003). No significant differences were detected for ADC values or MRI morphology concerning response and no correlations were present between FDG uptake and ADC values. The mean radiation dose was 5.9–6.5 mSv. We conclude that the combination of metabolic information and MRI morphology at a low radiation dose proposes PET/MR as a suitable imaging modality for AE assessment. Longitudinal studies are needed to define the role of this imaging modality. MDPI 2022-03-12 /pmc/articles/PMC8951377/ /pubmed/35335672 http://dx.doi.org/10.3390/pathogens11030348 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Eberhardt, Nina
Peters, Lynn
Kapp-Schwoerer, Silke
Beer, Meinrad
Beer, Ambros J.
Grüner, Beate
Thaiss, Wolfgang M.
18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting
title 18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting
title_full 18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting
title_fullStr 18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting
title_full_unstemmed 18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting
title_short 18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting
title_sort 18f-fdg-pet/mr in alveolar echinococcosis: multiparametric imaging in a real-world setting
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951377/
https://www.ncbi.nlm.nih.gov/pubmed/35335672
http://dx.doi.org/10.3390/pathogens11030348
work_keys_str_mv AT eberhardtnina 18ffdgpetmrinalveolarechinococcosismultiparametricimaginginarealworldsetting
AT peterslynn 18ffdgpetmrinalveolarechinococcosismultiparametricimaginginarealworldsetting
AT kappschwoerersilke 18ffdgpetmrinalveolarechinococcosismultiparametricimaginginarealworldsetting
AT beermeinrad 18ffdgpetmrinalveolarechinococcosismultiparametricimaginginarealworldsetting
AT beerambrosj 18ffdgpetmrinalveolarechinococcosismultiparametricimaginginarealworldsetting
AT grunerbeate 18ffdgpetmrinalveolarechinococcosismultiparametricimaginginarealworldsetting
AT thaisswolfgangm 18ffdgpetmrinalveolarechinococcosismultiparametricimaginginarealworldsetting